Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00932737 · ClinicalTrials.gov registry record · Phase 2

(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis

A Phase 2 study of Abdominal Pain, sponsored by Boehringer Ingelheim.

Completed
Registry status
Phase 2
Development phase
197
Enrollment target
19
Study locations

NCT00932737 is a Phase 2 study of Abdominal Pain that has completed, run by Boehringer Ingelheim. The registered enrollment target is 197 participants, above the 140-participant average among 19 other Abdominal Pain trials with a reported enrollment target (41% higher). The trial reports 19 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00932737, a Phase 2 study of Abdominal Pain, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
Phase 2
Development phase
197 participants
Enrollment target
19
Study locations

Study Summary

The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated with cramping (APC) in the treatment of two episodes.

Conditions Studied

Abdominal Pain

Interventions

  • DRUG Placebo
  • DRUG HBB 20 mg

Study Locations (19)

Florida

  • 202.839.01003 Boehringer Ingelheim Investigational Site - Hollywood
  • 202.839.01001 Boehringer Ingelheim Investigational Site - Jupiter
  • 202.839.01002 Boehringer Ingelheim Investigational Site - Jupiter

Oklahoma

  • 202.839.01021 Boehringer Ingelheim Investigational Site - Norman
  • 202.839.01010 Boehringer Ingelheim Investigational Site - Oklahoma City

Texas

  • 202.839.01006 Boehringer Ingelheim Investigational Site - San Antonio
  • 202.839.01012 Boehringer Ingelheim Investigational Site - San Antonio

California

  • 202.839.01014 Boehringer Ingelheim Investigational Site - Westlake Village

Illinois

  • 202.839.01017 Boehringer Ingelheim Investigational Site - Rockford

Indiana

  • 202.839.01005 Boehringer Ingelheim Investigational Site - Indianapolis

Maryland

  • 202.839.01019 Boehringer Ingelheim Investigational Site - Chevy Chase

Massachusetts

  • 202.839.01009 Boehringer Ingelheim Investigational Site - Boston

Trial Details

FieldValue
Enrollment Target 197 participants
Start Date 2009-06-09
Est. Completion 2010-02-08
Phase Phase 2

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00932737

The ClinicalTrials.gov registry entry for NCT00932737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 140-participant average among 19 other Abdominal Pain trials with a reported enrollment target (41% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Abdominal Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00932737 reports 19 study locations spanning 15 distinct geographic areas - top geographies include Florida, Oklahoma, Texas.

Frequently Asked Questions

What is clinical trial NCT00932737 about?

NCT00932737 is a clinical study titled "(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis". The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated with cramping (APC) in the treatment of two episodes.

What is the current status of trial NCT00932737?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2009-06-09. Estimated completion is 2010-02-08.

What conditions does trial NCT00932737 study?

This clinical trial studies the following conditions: Abdominal Pain.

What interventions are being tested in trial NCT00932737?

The interventions under investigation include: Placebo (DRUG), HBB 20 mg (DRUG).

Who is sponsoring clinical trial NCT00932737?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00932737 being conducted?

This trial has 19 study locations across California, Florida, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Abdominal Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Abdominal Pain

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.